Ann: ResApp Receives First Institutional Review Board Approval-RAP.AX, page-3

ResApp Receives First Institutional Review Board
Approval for SMARTCOUGH-C Study
Perth, Western Australia, 21 October 2016 -- ResApp Health Limited (ASX: RAP)
today announced that it is has received its first institutional review board (IRB)
approval for the SMARTCOUGH-C study, a prospective, multi-site, double blind
study that will evaluate the efficacy of the ResAppDx software application in the
diagnosis of childhood pneumonia and other respiratory conditions from cough
sounds.
Three US hospital sites are participating in the study, including Cleveland Clinic,
which is the first to secure institutional review board (IRB) approval to enrol
patients.
The primary endpoints for the study will be the diagnosis of pneumonia with
secondary endpoints being diagnosis of other common childhood respiratory
diseases such as upper respiratory tract infection, croup, bronchiolitis and
asthma. Today, respiratory disease diagnosis is based on a combination of
auscultation, imaging and laboratory tests. An instant, accurate diagnostic test
delivered via smartphone could greatly improve patient management, give
greater access to healthcare and reduce costs.
Worldwide, pneumonia is the leading cause of death of children under 5 years of
age and is the most common reason for US children to be hospitalised.
The Principal Investigator at Cleveland Clinic will be Dr. John Carl MD, Director of
the Center for Pediatric Pulmonary Medicine.
“We are very pleased to announce that we have received our first IRB approval for
our pivotal US pediatric study,” said Tony Keating, Managing Director and CEO of
ResApp. “Our ultimate goal is to demonstrate the clinical accuracy of ResAppDx
and improve healthcare for children everywhere.”